Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-09-11
2007-09-11
Wilson, Michael C. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100, C424S093200, C424S093210
Reexamination Certificate
active
09557907
ABSTRACT:
The present invention provides a pharmaceutical composition, comprising a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding an interferon ω and one or more cationic compounds. The present invention also provides methods of treating cancer in a mammal, comprising administering into a muscle of the mammal a non-infectious, non-integrating DNA polynucleotide construct comprising a polynucleotide encoding a cytokine. In addition, the present invention also relates to the methodology for selective transfection of malignant cells with polynucleotides expressing therapeutic or prophylactic molecules in intra-cavity tumor bearing mammals. More specifically, the present invention provides a methodology for the suppression of an intra-cavity dissemination of malignant cells, such as intraperitoneal dissemination. Furthermore, the invention relates to compositions and methods to deliver polynucleotides encoding polypeptides to vertebrate cells in vivo, where the composition comprises an aqueous solution of sodium phosphate.
REFERENCES:
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 4946787 (1990-08-01), Eppstein et al.
patent: 5049386 (1991-09-01), Eppstein et al.
patent: 5120832 (1992-06-01), Goeddel et al.
patent: 5229272 (1993-07-01), Paul et al.
patent: 5231176 (1993-07-01), Goeddel et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5268169 (1993-12-01), Brandely et al.
patent: 5314995 (1994-05-01), Fell, Jr. et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5578475 (1996-11-01), Jessee
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5641665 (1997-06-01), Hobart et al.
patent: 5676954 (1997-10-01), Brigham
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5827703 (1998-10-01), Debs et al.
patent: 5861397 (1999-01-01), Wheeler
patent: 5910488 (1999-06-01), Nabel et al.
patent: 5994317 (1999-11-01), Wheeler
patent: 6022874 (2000-02-01), Wheeler
patent: 6147055 (2000-11-01), Hobart et al.
patent: 6214804 (2001-04-01), Felgner et al.
patent: 6228844 (2001-05-01), Wolff et al.
patent: 6399588 (2002-06-01), Hobart et al.
patent: 6413942 (2002-07-01), Felgner et al.
patent: 6706694 (2004-03-01), Wolff et al.
patent: 6875748 (2005-04-01), Manthorpe et al.
patent: 2003/0186913 (2003-10-01), Wolf et al.
patent: 2003/0203863 (2003-10-01), Hobart et al.
patent: 2004/0023911 (2004-02-01), Felgner et al.
patent: 1 169 793 (1984-06-01), None
patent: 0 170 204 (1986-02-01), None
patent: 0 465 529 (1998-04-01), None
patent: WO90/11092 (1990-10-01), None
patent: WO91/14438 (1991-10-01), None
patent: WO94/29469 (1994-12-01), None
patent: WO95/09917 (1995-04-01), None
patent: WO95/14381 (1995-06-01), None
patent: WO95/14651 (1995-06-01), None
patent: WO95/17373 (1995-06-01), None
patent: WO96/18372 (1996-06-01), None
patent: WO96/26179 (1996-08-01), None
patent: WO96/40962 (1996-12-01), None
patent: WO96/40963 (1996-12-01), None
patent: WO96/41873 (1996-12-01), None
patent: WO97/00085 (1997-01-01), None
patent: WO97/00241 (1997-01-01), None
patent: WO97/30089 (1997-08-01), None
patent: WO98/08947 (1998-03-01), None
patent: WO99/26663 (1999-06-01), None
patent: WO99/64615 (1999-12-01), None
Henderson et al., Therapeutic potential of cytokine manipulation, 1992, Trends in Pharmacological Science, vol. 13, pp. 145-152.
Sedlacek et al., Vaccination for treatment of tumors: A critical comment, 1994, Critiacl Reviews in Oncogenesis, vol. 5, pp. 555-587.
Dalgleish et al., The development of therapeutic vaccines for the management of malignant melanoma, 1996, Skin Cancer, vol. 26, pp. 289-319.
Miller et al., Targeted vectors for gene therapy, 1995, FASEB J., vol. 9, pp. 190-199.
Deonarain, Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents, vol. 8, pp. 53-69.
Verma et al., Gene therapy-promises, problems and prospects, 1997, Nature, vol. 389, pp. 239-242.
Crystal, Transfer of genes to Humans: Early lessons and obstacles to success, 1995, Science, vol. 270, pp. 404-410.
Horton et al., A gene thearpy for cancer using intramuscular injection of plasmid DNA encoding interferon Alpha, 1999, Proc. Natl. Acad. Sci. USA, vol. 96, pp. 1553-1558.
Roth et al., Gene therapy for cancer: What have we done and where are we going?, 1997, Journal of the National Cancer Institute, vol. 89, pp. 21-39.
Lawson (J. Interferon and Cytokine Res., May 1997, vol. 17, p. 255-261).
Zhang (PNAS, Apr. 1996, vol. 93, p. 4513-4518).
Ogura (Cancer research, Aug. 15, 1990, vol. 50 (16) p. 5102-6).
Aoki (Human gene therapy, Jun. 10, 1997, vol. 8 (9) p. 1105-13).
Okamoto (Gene Therapy, 1997, vol. 4, p. 969-976).
Welander (Investigational New drugs, 1987, vol. 5, Suppl. S47-59, abstract only).
Horton (PNAS, Feb. 1999, vol. 96, p. 1553-1558).
Adachi, T., et al., “Tumoricidal effect of human macrophage-colony-stimulating factor against human-ovarian-carcinoma-bearing athymic mice and its therapeutic effect when combined with cisplatin,”Cancer Immunol. Immunother. 37:1-6 (1993).
Adolf, G.R., “Monoclonal Antibodies and Enzyme Immunoassays Specific for Human Interferon (IFN)ω1: Evidence that IFN-ω1 Is a Component of Human Leukocyte IFN,”Virology 175:410-417 (1990).
Adolf, G.R., et al., “Human interferon ω1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein,”Biochim. Biophys. Acta 1089:167-174 (1991).
Adolf, G.R., “Human interferon omega—a review,” Multiple Sclerosis 1:S44-S47 (1995).
Almadrones, L., et al., “Arterial, Peritoneal, and Intraventricular Access Devices,”Sem. Oncol. Nursing 11:194-202 (1995).
Aihara, H., and Miyazaki, J.-I., “Gene transfer into muscle by electroporation in vivo,”Nature Biotechnol. 16:867-870 (Sep. 1998).
Baron, S., et al., “The Interferons. Mechanisms of Action and Clinical Applications,”JAMA 266:1375-1383 (1991).
Bast Jr., R.C., et al., “Immunotherapy of a murine ovarian carcinoma withCorynebacterium parvumand specific heteroantiserum. I. Activation of Peritoneal Cells to Mediate Antibody-Dependent Cytotoxicity,”J. Immunol. 123:1945-1951 (1979).
Belldegrun, A., et al., “Human Renal Carcinoma Line Transfected With Interleukin-2 and/or Interferon α Gene(s): Implications for Live Cancer Vaccines,”J. Natl. Cancer Inst. 85:207-216 (1993).
Beller, U., et al., “Phase IB Study of Low-Dose Intraperitoneal Recombinant Interleukin-2 in Patients with Refractory Advanced Ovarian Cancer: Rationale and Preliminary Report,”Gynecol. Oncol.34:407-412 (1989).
Benedetti Panici, P., et al., “Recombinant interleukin-2 continuous infusion in ovarian cancer patients with minimal residual disease at second-look,”Cancer Treatment Rev. 16(Supplement A):123-127 (1989).
Berek, J.S., et al., “Immunotherapy with Biochemically Dissociated Fractions ofPropionibacterium acnesin a Murine Ovarian Cancer Model,”Cancer Res. 44:1871-1875 (1984).
Bramson, J., et al., “Construction of a Double Recombinant Adenovirus Vector Expressing a Heterodimeric Cytokine: In Vitro and In Vivo Production of Biologically Active Interleukin-12,”Hum. Gene Ther. 7:333-342 (Feb. 1996).
Budker, V., et al., “The efficient expression of intravascularly delivered DNA in rat muscle,”Gene Ther. 5:272-276 (1998).
Capon, D.J., et al., “Two Distinct Families of Human and Bovine Interferon-α Genes Are Coordinately Expressed and Encode Functional Polypeptides,”Mol. Cell. Biol. 5:768-779 (1985).
Chapman, P.B., et al., “A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma,”Investig. New Drugs 6:179-188 (1988).
Childers, J.M., et al., “Laparoscopic Surgical Staging of Ovarian Cancer,”Gynecol. Oncol. 59:25-33 (1995).
Clement, P.B., “Reactive Tumor-Like Lesions of the
Felgner Philip L.
Hartikka Jukka
Horton Holly
Manthorpe Marston
Parker Suezanne
Sterne Kessler Goldstein & Fox P.L.L.C.
Vical Incorporated
Wilson Michael C.
LandOfFree
Methods for treating cancer using cytokine-expressing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating cancer using cytokine-expressing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cancer using cytokine-expressing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3736811